Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 7257 pages

Showing 1 - 50


issues in oncology

Cancer Incidence, Curative Treatment, and Overall Survival in the English Prison Population

In a study reported in The Lancet Oncology, Lüchtenborg et al found that the incidence of cancer increased in the prison population in England between 1998 and 2017; those with cancer were less likely to receive curative treatment and had poorer overall survival vs patients with cancer in the...

gynecologic cancers

Advanced Ovarian Cancer: Adding Ruxolitinib to Front-Line Neoadjuvant Chemotherapy Plus Interval Debulking Surgery

In a phase I/II NRG Oncology Group study reported in the Journal of Clinical Oncology, Landen et al found that the addition of ruxolitinib to front-line paclitaxel/carboplatin neoadjuvant chemotherapy and interval debulking surgery improved progression-free survival in patients with stage III to IV ...

breast cancer

Early Breast Cancer: ALND or SLNB for ypN-Positive Disease After Neoadjuvant Chemotherapy

In an analysis of clinical trials reported in a research letter in JAMA Oncology, Brooks et al found no differences in long-term outcomes with the use of axillary lymph node dissection (ALND) vs sentinel lymph node biopsy (SLNB)—usually paired with adjuvant radiotherapy—among patients with breast...

colorectal cancer

Interval Between First Colonoscopy With Negative Findings and Repeat Colonoscopy

In a Swedish cohort study reported in JAMA Oncology, Liang et al found that among individuals with no family history of colorectal cancer and a negative first screening colonoscopy, the interval to repeat colonoscopy could be extended beyond the currently recommended 10 years. Study Details   The...

kidney cancer

KEYNOTE-564: Adjuvant Pembrolizumab Improves Overall Survival vs Placebo in Renal Cell Carcinoma

As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, FASCO, of Dana-Farber Cancer Institute and Harvard Medical School, and colleagues, the third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown significant benefit with adjuvant...

lung cancer

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK-Positive NSCLC

As reported in The New England Journal of Medicine by Yi‑Long Wu, MD, of Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, and colleagues, the phase III ALINA trial has shown significantly improved disease-free survival with adjuvant alectinib vs platinum-based chemotherapy...

gynecologic cancers

Noninferiority of Simple vs Radical Hysterectomy for Pelvic Recurrence in Low-Risk Cervical Cancer

As reported in The New England Journal of Medicine by Marie Plante, MD, of Centre Hospitalier Universitaire de Quebec, and colleagues, the phase III CX.5 SHAPE trial has shown noninferiority of simple vs radical hysterectomy in the frequency of pelvic recurrence in women with low-risk cervical...

lung cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Joel Neal, MD, PhD, and colleagues, the phase III CONTACT-01 trial has shown no significant improvement in overall survival with the tyrosine kinase inhibitor atezolizumab (multiple targets, including MET, AXL, VEGFR2, RET, and FLT) plus the...

breast cancer

Use of Topical Diclofenac Gel to Prevent Capecitabine-Associated Hand-Foot Syndrome

In an Indian single-center phase III trial (D-TORCH) reported in the Journal of Clinical Oncology, Santhosh et al found that the nonsteroidal, anti-inflammatory topical diclofenac gel significantly reduced the risk of capecitabine-associated hand-foot syndrome vs placebo gel in patients with breast ...

bladder cancer

Pembrolizumab in High-Risk Non–Muscle-Invasive Bladder Cancer

As reported in The Lancet Oncology by Andrea Necchi, MD, and colleagues, findings in cohort B of the phase II KEYNOTE-057 study indicated that pembrolizumab was active in patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer.  As noted by the...

issues in oncology

Outcomes for Cancer Drugs Initially FDA-Approved With Immature Overall Survival Data

In a study reported in The Lancet Oncology, Naci et al identified the degree to which initial U.S. Food and Drug Administration (FDA) approvals of cancer drugs based on immature overall survival data were subsequently followed by reporting of overall survival results. Study Details The study...

gastroesophageal cancer
gastrointestinal cancer

Advanced Gastric or Gastroesophageal Junction Cancer: Addition of Relatlimab to Immunochemotherapy

In the phase II RELATIVITY-060 study, results of which were reported in the Journal of Clinical Oncology, Susanna Hegewisch-Becker, MD, PhD, and colleagues found that the addition of the LAG-3–blocking antibody relatlimab to first-line nivolumab plus chemotherapy did not improve the objective...

lung cancer

Adding Perioperative Nivolumab to Neoadjuvant Chemotherapy in Resectable NSCLC: CheckMate 77T

As reported in The New England Journal of Medicine by Tina Cascone, MD, PhD, and colleagues, interim analysis in the phase III CheckMate 77T trial has shown that the addition of perioperative nivolumab to neoadjuvant chemotherapy improved event-free survival in patients with resectable non–small...

bladder cancer
immunotherapy

Nivolumab/Ipilimumab Boost in Metastatic Urothelial Carcinoma

In a German-Austrian phase II study (TITAN-TCC) reported in JAMA Oncology, Grimm et al described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma. Study Details In the multicenter trial, 169 patients were enrolled into two cohorts...

hepatobiliary cancer

Pertuzumab Plus Trastuzumab for Advanced Biliary Tract Cancer With HER2/3 Alterations

As reported in the Journal of Clinical Oncology by Cannon et al, findings in a cohort of the phase II Targeted Agent and Profiling Utilization Registry (TAPUR) basket study showed that the combination of pertuzumab and trastuzumab was active in patients with advanced biliary tract cancer with...

multiple myeloma

Multiple Myeloma: Is MRD Status at 1 Year After Treatment Predictive of Survival?

Results from the Prognostic Immunophenotyping in Myeloma Response (PRIMeR) study, reported in the Journal of Clinical Oncology by Marcelo C. Pasquini, MD, MS, and colleagues, found that undetectable measurable residual disease (MRD) status at 1 year after autologous hematopoietic cell...

gastroesophageal cancer

Definitive Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Cancer: Comparison of Agents

In a Chinese phase III trial (CRTCOESC) reported in the Journal of Clinical Oncology, Jia et al found that neither capecitabine nor XELOX (capecitabine, oxaliplatin) improved 2-year overall survival vs cisplatin/fluorouracil as part of definitive concurrent chemoradiotherapy in patients with...

breast cancer
supportive care
survivorship

Donepezil for the Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy

In the phase III WF-97116 trial reported in the Journal of Clinical Oncology, Rapp et al found that treatment with the cognitive enhancer donepezil did not improve memory or other cognitive functions vs placebo in breast cancer survivors with cancer-related cognitive impairment 1 to 5 years after...

lymphoma

Previously Untreated Mantle Cell Lymphoma: Ibrutinib, Immunochemotherapy, and ASCT

As reported in The Lancet by Martin Dreyling, MD, PhD, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell transplantation (ASCT) significantly improved failure-free...

kidney cancer

Marker for Distinguishing Renal Cell Carcinoma From Benign Renal Masses

In a study reported in the Journal of Clinical Oncology, Xu et al found that higher levels of preoperative plasma kidney injury molecule-1 (pKIM-1) distinguished renal cell carcinoma from benign renal masses. As stated by the investigators, “Both clear cell and papillary renal cell carcinoma...

solid tumors
genomics/genetics

T-DXd for Advanced Solid Tumors With Activating HER2 Mutations

As reported in The Lancet Oncology by Bob T. Li, MD, PhD, MPH, and colleagues, the phase II DESTINY-PanTumor01 trial showed activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with unresectable or metastatic solid tumors that have specific activating HER2 mutations. The antibody-drug...

genomics/genetics
survivorship

Childhood Cancer Survivors: Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus

In a study reported in the Journal of Clinical Oncology, Im et al found that genetic variants associated with a risk of treatment-related type 2 diabetes mellitus among childhood cancer survivors of African or European ancestry posed a higher risk of diabetes among those of African ancestry. As...

hematologic malignancies
lymphoma
leukemia
global cancer care

Lymphoid Neoplasms: European National Health Expenditure and Long-Term Survival

In an analysis of the EUROCARE-6 data set reported in The Lancet Oncology, Milena Sant, MD, and colleagues found that patients with lymphoid neoplasms from European countries with greater health expenditure had improved 10-year age-standardized relative survival. Study Details The study involved...

sarcoma

Doublet for Previously Treated Patients With Advanced Leiomyosarcoma

In a phase Ib study reported in the Journal of Clinical Oncology, Van Tine et al established the recommended phase II dose of oral unesbulin in combination with dacarbazine for patients with locally recurrent, unresectable or metastatic, relapsed or refractory leiomyosarcoma. Unesbulin is a small...

lymphoma
leukemia

Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent  Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...

hepatobiliary cancer

Pembrolizumab/Chemotherapy for Advanced Biliary Tract Cancer

On October 31, 2023, pembrolizumab (Keytruda) was approved for use with ­gemcitabine/cisplatin in first-line treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.1 Supporting Efficacy Data Approval was based on the double-blind KEYNOTE-966 trial...

kidney cancer

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, the hypoxia-inducible factor inhibitor belzutifan (Welireg) was approved for patients with unresectable locally advanced or metastatic clear cell renal cell carcinoma with disease progression on previous treatment with a PD-1 or PD-L1 inhibitor and a vascular endothelial...

bladder cancer

Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer

As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...

colorectal cancer

Cell-Free DNA Blood-Based Test and Next-Generation Multitarget Stool DNA Test in Colorectal Cancer Screening

In two studies reported in The New England Journal of Medicine, investigators found that a cell-free DNA (cfDNA) blood-based test (ECLIPSE study)1 and a next-generation multitarget stool DNA test (BLUE-C study)2 both showed high sensitivity for colorectal cancer and high specificity for advanced...

prostate cancer

Whole-Pelvic Radiation Therapy for Unfavorable-Risk Prostate Cancer

As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...

head and neck cancer
supportive care
symptom management

Head and Neck Cancer: Osteoradionecrosis of the Jaw Classification System

In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...

gynecologic cancers

Impact of Age on Outcomes in Endometrial Cancer

In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer.   Study Details The analysis included data from 1,801...

hepatobiliary cancer

Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer: PROs in TOPAZ-1

As reported in The Lancet Oncology by Howard A. Burris III, MD, FACP, FASCO, and colleagues, a patient-reported outcome (PRO) analysis from the phase III TOPAZ-1 trial showed no “detrimental effect” with the addition of durvalumab to gemcitabine/cisplatin in patients with advanced biliary tract...

breast cancer

Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer

In a retrospective cohort study reported in JAMA Oncology, Montagna et al found that patients with breast cancer with nodal downstaging after neoadjuvant chemotherapy had a low rate of axillary recurrence, with no difference observed for staging with targeted axillary dissection vs sentinel lymph...

gynecologic cancers

Local Recurrence of Endometrial Cancer: Radiotherapy With or Without Cisplatin

As reported in the Journal of Clinical Oncology by Ann H. Klopp, MD, PhD, and colleagues, results from an NRG Oncology/GOG trial showed “excellent” progression-free survival outcomes with radiation therapy alone for local recurrences of endometrial cancer, with the addition of cisplatin in...

colorectal cancer
hepatobiliary cancer

Hemihepatectomy: Outcomes With Laparoscopic vs Open Surgery

In a phase III study (ORANGE II PLUS) reported in the Journal of Clinical Oncology, Fichtinger et al found that among patients with indications for hemihepatectomy suitable for both laparoscopic and open approaches, of whom the majority had cancer, the laparoscopic approach was associated with a...

breast cancer

T-DXd vs Physician’s Choice of Therapy in HER2-Positive Metastatic Breast Cancer: PROs in DESTINY-Breast02

In an analysis of patient-reported outcomes (PROs) in the DESTINY-Breast02 trial published in The Lancet Oncology, Tanja Fehm, MD, and colleagues found that general health status/quality of life was maintained over time with fam-trastuzumab deruxtecan-nxki (T-DXd) vs physician’s choice of therapy...

breast cancer

Dato-DXd in Advanced or Metastatic HR-Positive/HER2-Negative or Triple-Negative Breast Cancer

In the phase I TROPION-PanTumor01 trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, PhD, and colleagues found that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) was active in patients with locally advanced or metastatic hormone receptor...

lung cancer

Durvalumab After Chemoradiotherapy in Unresectable NSCLC: Real-World Use and Outcomes

In a U.S. retrospective cohort study (SPOTLIGHT) reported in JAMA Network Open, Mooradian et al found that a substantial proportion of patients with unresectable stage III non–small cell lung cancer (NSCLC) did not receive consolidation durvalumab after chemoradiotherapy—but those who did had...

cardio-oncology

United Kingdom’s First Cardio-Oncology Service: 10-Year Experience

In a research letter published by Andres et al in JACC: CardioOncology, staff from Royal Brompton Hospital, Guy’s and St. Thomas’ NHS Foundation Trust in London described their experience over 10 years in the UK’s first cardio-oncology service. Study Details The study involved data from the initial ...

leukemia
lymphoma
immunotherapy

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma: CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

In a Chinese study reported in The New England Journal of Medicine, Hu et al found that sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was effective in patients with...

breast cancer

Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction

In a single-center phase II trial reported in JAMA Network Open, Schaverien et al found that a strategy of premastectomy radiotherapy and immediate breast reconstruction was feasible in patients undergoing surgery for breast cancer. Study Details A total of 49 patients with cT0–T3, N0–N3b breast...

lung cancer

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

As reported in the Journal of Clinical Oncology by David R. Spigel, MD, and colleagues, the phase III RESILIENT Part 2 trial has shown no overall survival benefit with second-line liposomal irinotecan vs topotecan in patients with small cell lung cancer whose disease progressed on or after...

cardio-oncology

Risk of Arterial Thromboembolism in Japanese Patients With Cancer

In a Japanese retrospective study reported in JACC:CardioOncology, Gon et al identified the incidence and outcomes of arterial thromboembolism in patients with cancer. Study Details The study used data on 97,448 patients with cancer (median age = 70 years) from the Osaka Cancer Registry linked with ...

bladder cancer
genomics/genetics

Metastatic Urothelial Cancer: NECTIN4 Amplification and Response to Enfortumab Vedotin

In a study reported in the Journal of Clinical Oncology, Klümper et al established a fluorescence in situ hybridization (FISH) assay to measure NECTIN4 copy number variations and found that NECTIN4 amplification was associated with high activity of the anti-NECTIN4 antibody-drug conjugate...

prostate cancer

Salvage Reirradiation for Locally Recurrent Prostate Cancer: 7-Year Follow-up

In an update of a Norwegian trial reported in the Journal of Clinical Oncology, Ekanger et al found that long term, salvage reirradiation for locally recurrent prostate cancer was feasible and associated with good outcomes. Study Details The study included 38 patients with locally recurrent disease ...

prostate cancer

Metastatic Castration-Resistant Prostate Cancer: Addition of LuPSMA to Enzalutamide

In an interim analysis of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved prostate-specific antigen (PSA) progression-free survival in the first-line treatment of patients...

leukemia

Pediatric AML: Comparison of Induction Regimens

In the phase III AML2012 trial, which had early termination of enrollment and results of which were reported in the Journal of Clinical Oncology, Tierens et al found that mitoxantrone-based induction resulted in better outcomes vs liposomal daunorubicin–based induction in pediatric patients with...

lymphoma
geriatric oncology
cardio-oncology

Older Patients With Newly Diagnosed Hodgkin Lymphoma: Preexisting Heart Failure and Survival Outcomes

In a study reported in JACC: CardioOncology, Upshaw et al found that preexisting heart failure was associated with an increased risk of lymphoma and cardiovascular mortality among patients aged ≥ 65 years who were newly diagnosed with Hodgkin lymphoma. The study used linked Surveillance,...

leukemia
survivorship

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL

In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with...

Advertisement

Advertisement




Advertisement